SCHEMBL2472224

SCHEMBL2472224

COCCN(C)S(=O)(=O)C(NC(=O)c1ccccc1OC)C1(c2cccc(F)c2)CCCNCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
KCNA3 P22001 4/20 0.35
CHRM3 P20309 1/20 0.34
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
REN P00797 1/20 0.33
ITGB1 P05556 3/20 0.33
ITGA4 P13612 3/20 0.33
ITGB7 P26010 3/20 0.33
CCR3 P51677 1/20 0.33
SLC6A9 P48067 1/20 0.33
CCR8 P51685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465586 0.92 SMN1; SMN2 (0.41) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2472317 0.92 ALDH1A1 (0.41) MEN1KMT2AALDH1A1KCNA3ITGB1
SCHEMBL2470113 0.86 SMN1; SMN2 (0.42) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2470303 0.84 NPC1 (0.39) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2467688 0.84 KDM4E (0.44) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2465785 0.83 GAA (0.40) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2918002 0.83 SMN1; SMN2 (0.43) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2473766 0.82 SMN1; SMN2 (0.44) NPC1LMNAPKMRAB9ASMN1; SMN2
SCHEMBL2468321 0.82 ALDH1A1 (0.44) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2468237 0.82 ALDH1A1 (0.42) MEN1KMT2AALDH1A1KCNA3ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 NPC1 989/4885LMNA 1070/4885PKM 675/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 NPC1 989/4885LMNA 1070/4885PKM 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.